H4ZB:F:F-HSBC FTSE 100 (EUR)

ETF | Others |

Last Closing

USD 86.98

Change

0.00 (0.00)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-28 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

-0.94 (-0.18%)

USD 101.74B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.36 (+0.73%)

USD 101.37B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 96.03B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 57.02B
XJSE:F Xtrackers II - Japan Governmen..

+0.07 (+0.97%)

USD 53.72B
VUSA:F Vanguard Funds Public Limited ..

-1.10 (-1.19%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+1.00 (+0.45%)

USD 45.80B
0ZC:F Zscaler Inc

+0.24 (+0.13%)

USD 37.92B
BSND:F Danone SA

-0.30 (-2.03%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

+0.42 (+0.35%)

USD 24.77B

ETFs Containing H4ZB:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 24.76% 40% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.76% 41% F 35% F
Average Annual (5 Year Horizon)  
Capital Gain 6.10% 56% F 57% F
Dividend Return 6.10% 53% F 49% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 9.51% 69% C- 92% A
Risk Adjusted Return 64.09% 64% D 74% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike